MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160), a spin-off of China-based MicroPort Scientific Corp (HKG: 0853), has announced that it has received marketing approval in Colombia for its in-house developed Alwide Plus balloon catheter. This marks another significant milestone in the global expansion of the company’s cardiovascular product portfolio.
Product Overview and Features
Alwide Plus is an upgraded version of MicroPort CardioFlow’s Alwide balloon catheter, which was approved for marketing in China in July 2021. The product has also received approval in Argentina in March 2022. Alwide Plus features low compliance, enabling more accurate balloon dilation size, high burst pressure suitable for severely calcified lesions, and rapid filling/retraction that can minimize pacing time. Designed to increase burst pressure, Alwide Plus reduces the difficulty of valve pre-dilation and post-dilation in Transcatheter Aortic Valve Implantation (TAVI) procedures.
Global Expansion and Future Outlook
The approval in Colombia underscores MicroPort CardioFlow’s commitment to expanding its global footprint and bringing innovative cardiovascular solutions to patients worldwide. With its advanced features and regulatory approvals, Alwide Plus is well-positioned to address the needs of healthcare providers and improve patient outcomes in transcatheter procedures.-Fineline Info & Tech
